10x Genomics, Inc. (NASDAQ: TXG) Stock Competitors & Peer Comparison
See TXG's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TXG and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TXG | $73.12 | -2.75% | 9.1B | -121.68 | -$0.59 | N/A |
| VRTX | $496.08 | -2.15% | 123.2B | 25.50 | $19.03 | N/A |
| MRNA | $219.50 | +2.69% | 85.8B | -26.53 | -$8.15 | N/A |
| REGN | $775.43 | +1.65% | 77.6B | 16.50 | $45.63 | +0.49% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $825.03 | +1.57% | 50.5B | 28.94 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $195.16 | +0.62% | 40.1B | -21.37 | -$8.82 | N/A |
| ONC | $352.97 | +0.73% | 37.3B | 61.46 | $5.68 | N/A |
| RVMDW | $10.14 | +0.60% | 37.1B | -1.07 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TXG vs VRTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, VRTX has a market cap of 123.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while VRTX trades at $496.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas VRTX's P/E ratio is 25.50. In terms of profitability, TXG's ROE is -0.09%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, TXG is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
TXG vs MRNA Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, MRNA has a market cap of 85.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while MRNA trades at $219.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas MRNA's P/E ratio is -26.53. In terms of profitability, TXG's ROE is -0.09%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TXG is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TXG vs REGN Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, REGN has a market cap of 77.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while REGN trades at $775.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas REGN's P/E ratio is 16.50. In terms of profitability, TXG's ROE is -0.09%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TXG is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
TXG vs VRNA Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TXG's ROE is -0.09%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, TXG is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TXG.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TXG vs ARGX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ARGX has a market cap of 50.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ARGX trades at $825.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ARGX's P/E ratio is 28.94. In terms of profitability, TXG's ROE is -0.09%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, TXG is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
TXG vs SGEN Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TXG's ROE is -0.09%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TXG is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TXG vs RVMD Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RVMD has a market cap of 40.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RVMD trades at $195.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RVMD's P/E ratio is -21.37. In terms of profitability, TXG's ROE is -0.09%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, TXG is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
TXG vs ONC Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ONC has a market cap of 37.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ONC trades at $352.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ONC's P/E ratio is 61.46. In terms of profitability, TXG's ROE is -0.09%, compared to ONC's ROE of +0.14%. Regarding short-term risk, TXG is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ONC's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TXG vs RVMDW Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RVMDW has a market cap of 37.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RVMDW trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RVMDW's P/E ratio is -1.07. In terms of profitability, TXG's ROE is -0.09%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, TXG is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TXG.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TXG vs ALNY Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ALNY has a market cap of 29.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ALNY trades at $224.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ALNY's P/E ratio is 40.33. In terms of profitability, TXG's ROE is -0.09%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TXG is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TXG vs ROIV Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ROIV has a market cap of 24.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ROIV trades at $33.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ROIV's P/E ratio is -31.73. In terms of profitability, TXG's ROE is -0.09%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, TXG is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TXG vs UTHR Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while UTHR trades at $537.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas UTHR's P/E ratio is 19.44. In terms of profitability, TXG's ROE is -0.09%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, TXG is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for TXG.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
TXG vs GMAB Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, GMAB has a market cap of 22.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while GMAB trades at $36.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas GMAB's P/E ratio is 27.56. In terms of profitability, TXG's ROE is -0.09%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, TXG is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for TXG.Check GMAB's competition here
BioNTech SE (NASDAQ: BNTX)
TXG vs BNTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, BNTX has a market cap of 22.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while BNTX trades at $89.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas BNTX's P/E ratio is -11.54. In terms of profitability, TXG's ROE is -0.09%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, TXG is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
TXG vs INCY Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, INCY has a market cap of 22B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while INCY trades at $111.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas INCY's P/E ratio is 14.60. In terms of profitability, TXG's ROE is -0.09%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TXG is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for TXG.Check INCY's competition here
Insmed Incorporated (NASDAQ: INSM)
TXG vs INSM Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, INSM has a market cap of 21B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while INSM trades at $96.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas INSM's P/E ratio is -23.55. In terms of profitability, TXG's ROE is -0.09%, compared to INSM's ROE of -1.11%. Regarding short-term risk, TXG is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TXG vs BGNE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TXG's ROE is -0.09%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, TXG is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TXG vs DNA-WT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.09%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, TXG is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TXG vs EXEL Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, EXEL has a market cap of 15B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while EXEL trades at $60.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas EXEL's P/E ratio is 17.00. In terms of profitability, TXG's ROE is -0.09%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, TXG is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for TXG.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TXG vs ASND Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ASND has a market cap of 13.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ASND trades at $225.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ASND's P/E ratio is -92.24. In terms of profitability, TXG's ROE is -0.09%, compared to ASND's ROE of +1.90%. Regarding short-term risk, TXG is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TXG vs NBIX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, NBIX has a market cap of 13.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while NBIX trades at $135.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas NBIX's P/E ratio is 19.53. In terms of profitability, TXG's ROE is -0.09%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TXG is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TXG vs JAZZ Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, JAZZ has a market cap of 13.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while JAZZ trades at $214.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas JAZZ's P/E ratio is 7.84. In terms of profitability, TXG's ROE is -0.09%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, TXG is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for TXG.Check JAZZ's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TXG vs HALO Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, HALO has a market cap of 13B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while HALO trades at $117.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas HALO's P/E ratio is 20.45. In terms of profitability, TXG's ROE is -0.09%, compared to HALO's ROE of +1.81%. Regarding short-term risk, TXG is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for TXG.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TXG vs KRTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TXG's ROE is -0.09%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TXG is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check KRTX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TXG vs BBIO Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, BBIO has a market cap of 12.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while BBIO trades at $64.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas BBIO's P/E ratio is -16.93. In terms of profitability, TXG's ROE is -0.09%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, TXG is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for TXG.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TXG vs SMMT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, SMMT has a market cap of 12.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while SMMT trades at $15.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas SMMT's P/E ratio is -13.86. In terms of profitability, TXG's ROE is -0.09%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TXG is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SMMT's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TXG vs TECH Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while TECH trades at $72.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas TECH's P/E ratio is 37.36. In terms of profitability, TXG's ROE is -0.09%, compared to TECH's ROE of +0.09%. Regarding short-term risk, TXG is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TXG vs RNAM Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TXG's ROE is -0.09%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, TXG is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TXG vs BMRN Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, BMRN has a market cap of 10.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while BMRN trades at $54.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas BMRN's P/E ratio is 26.14. In terms of profitability, TXG's ROE is -0.09%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, TXG is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TXG vs MDGL Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, MDGL has a market cap of 10.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while MDGL trades at $455.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas MDGL's P/E ratio is -35.32. In terms of profitability, TXG's ROE is -0.09%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TXG is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MDGL's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TXG vs IBRX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, IBRX has a market cap of 10.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while IBRX trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas IBRX's P/E ratio is -10.10. In terms of profitability, TXG's ROE is -0.09%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, TXG is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check IBRX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TXG vs PCVX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, PCVX has a market cap of 9.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while PCVX trades at $67.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas PCVX's P/E ratio is -8.75. In terms of profitability, TXG's ROE is -0.09%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, TXG is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check PCVX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TXG vs RXDX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TXG's ROE is -0.09%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TXG is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TXG vs KRYS Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while KRYS trades at $324.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas KRYS's P/E ratio is 40.25. In terms of profitability, TXG's ROE is -0.09%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TXG is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for TXG.Check KRYS's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
TXG vs TWST Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, TWST has a market cap of 9.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while TWST trades at $150.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas TWST's P/E ratio is -68.17. In terms of profitability, TXG's ROE is -0.09%, compared to TWST's ROE of -0.30%. Regarding short-term risk, TXG is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TWST's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TXG vs NUVL Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TXG's ROE is -0.09%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TXG is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TXG.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TXG vs CRNX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CRNX's P/E ratio is -16.86. In terms of profitability, TXG's ROE is -0.09%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TXG is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TXG vs PTGX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, PTGX has a market cap of 8.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while PTGX trades at $136.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas PTGX's P/E ratio is 134.46. In terms of profitability, TXG's ROE is -0.09%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, TXG is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TXG vs KYMR Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while KYMR trades at $106.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas KYMR's P/E ratio is -33.34. In terms of profitability, TXG's ROE is -0.09%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, TXG is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for TXG.Check KYMR's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TXG vs IMGN Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TXG's ROE is -0.09%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TXG is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check IMGN's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TXG vs APGE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas APGE's P/E ratio is -31.19. In terms of profitability, TXG's ROE is -0.09%, compared to APGE's ROE of -0.30%. Regarding short-term risk, TXG is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TXG vs BPMC Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TXG's ROE is -0.09%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TXG is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TXG.Check BPMC's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TXG vs CAI Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CAI has a market cap of 8.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CAI trades at $30.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CAI's P/E ratio is 82.97. In terms of profitability, TXG's ROE is -0.09%, compared to CAI's ROE of +0.19%. Regarding short-term risk, TXG is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TXG.Check CAI's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
TXG vs TGTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while TGTX trades at $54.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas TGTX's P/E ratio is 19.69. In terms of profitability, TXG's ROE is -0.09%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, TXG is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TXG vs CERE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CERE's P/E ratio is -16.47. In terms of profitability, TXG's ROE is -0.09%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TXG is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CERE's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TXG vs ARWR Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ARWR trades at $57.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ARWR's P/E ratio is -25.84. In terms of profitability, TXG's ROE is -0.09%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, TXG is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ARWR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TXG vs AXSM Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, AXSM has a market cap of 8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while AXSM trades at $160.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas AXSM's P/E ratio is -40.81. In terms of profitability, TXG's ROE is -0.09%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, TXG is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check AXSM's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TXG vs CYTK Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CYTK has a market cap of 7.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CYTK trades at $63.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CYTK's P/E ratio is -8.53. In terms of profitability, TXG's ROE is -0.09%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, TXG is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
TXG vs MTSR Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TXG's ROE is -0.09%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, TXG is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TXG vs IONS Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, IONS has a market cap of 7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while IONS trades at $42.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas IONS's P/E ratio is -12.96. In terms of profitability, TXG's ROE is -0.09%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TXG is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for TXG.Check IONS's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TXG vs SYRE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, SYRE has a market cap of 7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while SYRE trades at $78.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas SYRE's P/E ratio is -41.26. In terms of profitability, TXG's ROE is -0.09%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, TXG is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SYRE's competition here
Merus N.V. (NASDAQ: MRUS)
TXG vs MRUS Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TXG's ROE is -0.09%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, TXG is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MRUS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TXG vs PRAX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while PRAX trades at $239.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas PRAX's P/E ratio is -18.82. In terms of profitability, TXG's ROE is -0.09%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, TXG is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check PRAX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TXG vs ACLX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TXG's ROE is -0.09%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, TXG is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TXG vs RETA Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RETA's P/E ratio is -66.29. In terms of profitability, TXG's ROE is -0.09%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TXG is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RETA's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
TXG vs IOVA Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, IOVA has a market cap of 6.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while IOVA trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas IOVA's P/E ratio is -19.86. In terms of profitability, TXG's ROE is -0.09%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, TXG is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for TXG.Check IOVA's competition here
Abivax S.A. (NASDAQ: ABVX)
TXG vs ABVX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ABVX has a market cap of 6.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ABVX trades at $87.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ABVX's P/E ratio is -14.13. In terms of profitability, TXG's ROE is -0.09%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, TXG is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ABVX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TXG vs CNTA Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TXG's ROE is -0.09%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TXG is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CNTA's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TXG vs TERN Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas TERN's P/E ratio is -51.41. In terms of profitability, TXG's ROE is -0.09%, compared to TERN's ROE of -0.14%. Regarding short-term risk, TXG is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TERN's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TXG vs BLTE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while BLTE trades at $153.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas BLTE's P/E ratio is -81.21. In terms of profitability, TXG's ROE is -0.09%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, TXG is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TXG vs LGND Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while LGND trades at $302.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas LGND's P/E ratio is 33.32. In terms of profitability, TXG's ROE is -0.09%, compared to LGND's ROE of +0.20%. Regarding short-term risk, TXG is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for TXG.Check LGND's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TXG vs RYTM Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RYTM trades at $87.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RYTM's P/E ratio is -27.89. In terms of profitability, TXG's ROE is -0.09%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, TXG is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RYTM's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TXG vs IMVT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while IMVT trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas IMVT's P/E ratio is -10.18. In terms of profitability, TXG's ROE is -0.09%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, TXG is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check IMVT's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
TXG vs KOD Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, KOD has a market cap of 5.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while KOD trades at $84.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas KOD's P/E ratio is -21.97. In terms of profitability, TXG's ROE is -0.09%, compared to KOD's ROE of -2.73%. Regarding short-term risk, TXG is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for TXG.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TXG vs CDTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TXG's ROE is -0.09%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, TXG is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
TXG vs ABCM Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TXG's ROE is -0.09%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TXG is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TXG vs ISEE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TXG's ROE is -0.09%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TXG is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ISEE's competition here
CG Oncology Inc. (NASDAQ: CGON)
TXG vs CGON Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CGON trades at $61.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CGON's P/E ratio is -23.20. In terms of profitability, TXG's ROE is -0.09%, compared to CGON's ROE of -0.25%. Regarding short-term risk, TXG is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CGON's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TXG vs APLS Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas APLS's P/E ratio is 38.35. In terms of profitability, TXG's ROE is -0.09%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TXG is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TXG.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
TXG vs ERAS Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ERAS trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ERAS's P/E ratio is -15.89. In terms of profitability, TXG's ROE is -0.09%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, TXG is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ERAS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TXG vs PTCT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, PTCT has a market cap of 5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while PTCT trades at $59.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas PTCT's P/E ratio is -25.70. In terms of profitability, TXG's ROE is -0.09%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TXG is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TXG vs SRRK Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, SRRK has a market cap of 4.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while SRRK trades at $39.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas SRRK's P/E ratio is -11.74. In terms of profitability, TXG's ROE is -0.09%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, TXG is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SRRK's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TXG vs MIRM Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, MIRM has a market cap of 4.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while MIRM trades at $79.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas MIRM's P/E ratio is -5.47. In terms of profitability, TXG's ROE is -0.09%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, TXG is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MIRM's competition here
Veradermics, Incorporated (NYSE: MANE)
TXG vs MANE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while MANE trades at $113.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas MANE's P/E ratio is -37.00. In terms of profitability, TXG's ROE is -0.09%, compared to MANE's ROE of -0.38%. Regarding short-term risk, TXG is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MANE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TXG vs CRSP Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CRSP trades at $50.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CRSP's P/E ratio is -10.53. In terms of profitability, TXG's ROE is -0.09%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, TXG is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CRSP's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TXG vs TVTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while TVTX trades at $52.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas TVTX's P/E ratio is -115.11. In terms of profitability, TXG's ROE is -0.09%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, TXG is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TVTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TXG vs COGT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, COGT has a market cap of 4.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while COGT trades at $27.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas COGT's P/E ratio is -13.31. In terms of profitability, TXG's ROE is -0.09%, compared to COGT's ROE of -0.73%. Regarding short-term risk, TXG is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check COGT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TXG vs ORKA Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ORKA has a market cap of 4.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ORKA trades at $75.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ORKA's P/E ratio is -40.30. In terms of profitability, TXG's ROE is -0.09%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, TXG is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ORKA's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TXG vs DFTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while DFTX trades at $34.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas DFTX's P/E ratio is N/A. In terms of profitability, TXG's ROE is -0.09%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, TXG is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TXG vs FOLD Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TXG's ROE is -0.09%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, TXG is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TXG.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TXG vs AKRO Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TXG's ROE is -0.09%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, TXG is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TXG.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TXG vs ALPN Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TXG's ROE is -0.09%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TXG is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ALPN's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TXG vs DNTH Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while DNTH trades at $75.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas DNTH's P/E ratio is -18.69. In terms of profitability, TXG's ROE is -0.09%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, TXG is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for TXG.Check DNTH's competition here
Opthea Limited (NASDAQ: OPT)
TXG vs OPT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas OPT's P/E ratio is -1.52. In terms of profitability, TXG's ROE is -0.09%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TXG is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
TXG vs PRTC Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TXG's ROE is -0.09%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TXG is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for TXG.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TXG vs MRTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TXG's ROE is -0.09%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TXG is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check MRTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TXG vs ADPT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ADPT trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ADPT's P/E ratio is -61.66. In terms of profitability, TXG's ROE is -0.09%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, TXG is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ADPT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TXG vs EWTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, EWTX has a market cap of 3.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while EWTX trades at $37.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas EWTX's P/E ratio is -19.61. In terms of profitability, TXG's ROE is -0.09%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, TXG is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check EWTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TXG vs CPRX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CPRX's P/E ratio is 17.49. In terms of profitability, TXG's ROE is -0.09%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TXG is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
TXG vs ABCL Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ABCL trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ABCL's P/E ratio is -23.35. In terms of profitability, TXG's ROE is -0.09%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, TXG is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ABCL's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
TXG vs RLAY Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RLAY has a market cap of 3.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RLAY trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RLAY's P/E ratio is -11.06. In terms of profitability, TXG's ROE is -0.09%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, TXG is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RLAY's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
TXG vs RYZB Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TXG's ROE is -0.09%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TXG is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TXG.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
TXG vs CBAY Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TXG's ROE is -0.09%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TXG is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for TXG.Check CBAY's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
TXG vs TLX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while TLX trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas TLX's P/E ratio is 113.99. In terms of profitability, TXG's ROE is -0.09%, compared to TLX's ROE of +0.07%. Regarding short-term risk, TXG is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TLX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
TXG vs TNGX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while TNGX trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas TNGX's P/E ratio is -26.77. In terms of profitability, TXG's ROE is -0.09%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, TXG is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check TNGX's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
TXG vs SWTX Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas SWTX's P/E ratio is -13.78. In terms of profitability, TXG's ROE is -0.09%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, TXG is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for TXG.Check SWTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
TXG vs XENE Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, XENE has a market cap of 3.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while XENE trades at $33.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas XENE's P/E ratio is -7.32. In terms of profitability, TXG's ROE is -0.09%, compared to XENE's ROE of -0.44%. Regarding short-term risk, TXG is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for TXG.Check XENE's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
TXG vs LEGN Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while LEGN trades at $19.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas LEGN's P/E ratio is -26.29. In terms of profitability, TXG's ROE is -0.09%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, TXG is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for TXG.Check LEGN's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
TXG vs ARQT Comparison October 2026
10x Genomics, Inc. (NASDAQ: TXG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXG stands at 9.1B. In comparison, ARQT has a market cap of 3.3B. Regarding current trading prices, TXG is priced at $73.12 on the NASDAQ, while ARQT trades at $26.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXG currently has a P/E ratio of -121.68, whereas ARQT's P/E ratio is 124.24. In terms of profitability, TXG's ROE is -0.09%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, TXG is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for TXG.Check ARQT's competition here